Raloxifene for older women: a review of the literature

Helga HansdóttirDepartment of Geriatrics, Landspitali University Hospital, Landakoti, Reykjavik, IcelandAbstract: Raloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which is used for prevention and treatment of postmenopausal osteoporosis. Raloxifene decreases the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Helga Hansdóttir
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/6bc9696e6b4b436ba926d8eb3399efcb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6bc9696e6b4b436ba926d8eb3399efcb
record_format	dspace
spelling	oai:doaj.org-article:6bc9696e6b4b436ba926d8eb3399efcb2021-12-02T11:29:22ZRaloxifene for older women: a review of the literature1178-1998https://doaj.org/article/6bc9696e6b4b436ba926d8eb3399efcb2008-03-01T00:00:00Zhttps://www.dovepress.com/raloxifene-for-older-women-a-review-of-the-literature-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Helga HansdóttirDepartment of Geriatrics, Landspitali University Hospital, Landakoti, Reykjavik, IcelandAbstract: Raloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which is used for prevention and treatment of postmenopausal osteoporosis. Raloxifene decreases the incidence of vertebral fractures by 30%–50% in postmenopausal women with osteoporosis but has not been shown to decrease the incidence of hip fractures or other non-vertebral fractures. At the present time, estrogen-replacement therapy and bisphosphonate treatment are the only medical treatments that are proven to prevent hip fractures with the exception of vitamin D and calcium replacement, which has been shown to prevent hip fractures in elderly individuals and nursing home residents. Raloxifene has been shown to have additive effects on bone turnover and bone mineral density (BMD) when used along with alendronate and teriparatide. Raloxifene could have a role in renal failure as it has been shown to increase BMD of the vertebra over 1 year of therapy. Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer. The increased incidence of venous thromboembolism is the main concern of raloxifene therapy and previous history of venous thromboembolism is a contraindication for use of raloxifene. Raloxifene has a role in treatment of vertebral osteoporosis in older women. The decision to use raloxifene should be based on evaluation of fracture risk and on potential other benefits than fracture reduction along with consideration of side effects.Keywords: SERM, raloxifene, osteoporosis, women, fractures, old ageHelga HansdóttirDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 45-50 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Helga Hansdóttir Raloxifene for older women: a review of the literature
description	Helga HansdóttirDepartment of Geriatrics, Landspitali University Hospital, Landakoti, Reykjavik, IcelandAbstract: Raloxifene is a non-steroidal selective estrogen-receptor modulator (SERM) which is used for prevention and treatment of postmenopausal osteoporosis. Raloxifene decreases the incidence of vertebral fractures by 30%–50% in postmenopausal women with osteoporosis but has not been shown to decrease the incidence of hip fractures or other non-vertebral fractures. At the present time, estrogen-replacement therapy and bisphosphonate treatment are the only medical treatments that are proven to prevent hip fractures with the exception of vitamin D and calcium replacement, which has been shown to prevent hip fractures in elderly individuals and nursing home residents. Raloxifene has been shown to have additive effects on bone turnover and bone mineral density (BMD) when used along with alendronate and teriparatide. Raloxifene could have a role in renal failure as it has been shown to increase BMD of the vertebra over 1 year of therapy. Raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer. The increased incidence of venous thromboembolism is the main concern of raloxifene therapy and previous history of venous thromboembolism is a contraindication for use of raloxifene. Raloxifene has a role in treatment of vertebral osteoporosis in older women. The decision to use raloxifene should be based on evaluation of fracture risk and on potential other benefits than fracture reduction along with consideration of side effects.Keywords: SERM, raloxifene, osteoporosis, women, fractures, old age
format	article
author	Helga Hansdóttir
author_facet	Helga Hansdóttir
author_sort	Helga Hansdóttir
title	Raloxifene for older women: a review of the literature
title_short	Raloxifene for older women: a review of the literature
title_full	Raloxifene for older women: a review of the literature
title_fullStr	Raloxifene for older women: a review of the literature
title_full_unstemmed	Raloxifene for older women: a review of the literature
title_sort	raloxifene for older women: a review of the literature
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/6bc9696e6b4b436ba926d8eb3399efcb
work_keys_str_mv	AT helgahansdoacutettir raloxifeneforolderwomenareviewoftheliterature
_version_	1718395882952458240

Raloxifene for older women: a review of the literature

Ejemplares similares